COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00912015
Recruitment Status : Completed
First Posted : June 3, 2009
Results First Posted : June 3, 2009
Last Update Posted : April 30, 2012
Information provided by (Responsible Party):
Labopharm Inc.

Brief Summary:
The purpose of this study is to evaluate the long-term safety (up to one year) of Tramadol Once-A-Day (OAD) tablets at the highest doses: 200-400 mg

Condition or disease Intervention/treatment Phase
Pain Osteoarthritis, Knee Drug: Tramadol OAD Drug: Tramadol OAD 100mg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 238 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up
Study Start Date : March 2002
Actual Primary Completion Date : July 2003
Actual Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Tramadol

Arm Intervention/treatment
Experimental: Tramadol OAD 200mg Drug: Tramadol OAD
Experimental: Tramadol OAD 300mg Drug: Tramadol OAD
Experimental: Tramadol OAD 400mg Drug: Tramadol OAD
Tramadol OAD 100mg
Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
Drug: Tramadol OAD 100mg

Primary Outcome Measures :
  1. Adverse Events: 12-months Safety Population [ Time Frame: 12 months ]
    Spontaneous adverse events were recorded for patients who received the same dose for at least 350 days. A treatment emergent adverse event (TEAE) was associated to the dose level on which a patient was 2 days prior to the TEAE. Only TEAEs which could be associated with the dose level on which the patient was for the longest time were considered.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the ACR Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):

    • Current knee pain,
    • Less than 30 minutes of morning stiffness with or without crepitus on active motion.
    • Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within one year prior to entry into the study.
  2. ESR < 40 mm/hour
  3. WOMAC Pain Subscales total score of more than or equal to 150 mm at baseline.
  4. Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
  5. The Patient has signed and dated the REB approved, written, informed consent prior to study participation.

Exclusion Criteria:

  1. Known rheumatoid arthritis or any other rheumatoid disease.
  2. Secondary arthritis, i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.
  3. Obesity Class II (BMI more than or equal to 35) (NIH, 2000)
  4. Major illness requiring hospitalization during the 3 months before commencement of the screening period.
  5. Unwillingness to cease taking medication other than the study medication for arthritic pain, any other concomitant pain, or OA medications.
  6. Patients who have previously failed tramadol HCl therapy or those who discontinued tramadol HCl due to adverse events.
  7. Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.
  8. Patients who are taking or have taken another investigational agent within the last 30 days.
  9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.
  10. Patients who are opioid dependent.
  11. Patients with bowel disease causing malabsorption.
  12. Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.
  13. Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
  14. Patients with significant renal disease, defined as creatinine clearance <30 mL/min as estimated by the method of Levey et al., 1999.
  15. Current substance abuse or dependence, other than nicotine.
  16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.
  17. Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
Layout table for additonal information
Responsible Party: Labopharm Inc. Identifier: NCT00912015    
Other Study ID Numbers: MDT3-001-E1-A1
First Posted: June 3, 2009    Key Record Dates
Results First Posted: June 3, 2009
Last Update Posted: April 30, 2012
Last Verified: April 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents